Septuagenarian population has similar survival and outcomes to younger patients after left ventricular assist device implantation.

Assistance cardiaque ventriculaire gauche Complications de LVAD Elderly patients LVAD-related complications Left ventricular assist device Patients âgés Septuagenarians Septuagénaires Survie Survival

Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 06 03 2020
revised: 20 03 2020
accepted: 12 05 2020
pubmed: 22 9 2020
medline: 16 12 2020
entrez: 21 9 2020
Statut: ppublish

Résumé

Left ventricular assist device (LVAD) implantation may be an attractive alternative therapeutic option for elderly patients with heart failure who are ineligible for heart transplantation. We aimed to describe the characteristics and outcomes of elderly patients (i.e. aged≥70 years) receiving an LVAD. This observational study was conducted in 19 centres between 2006 and 2016. Patients were divided into two groups-younger (aged<70 years) and elderly (aged≥70 years), based on age at time of LVAD implantation. A total of 652 patients were included in the final analysis, and 74 patients (11.3%) were aged≥70 years at the time of LVAD implantation (maximal age 77.6 years). The proportion of elderly patients receiving an LVAD each year was constant, with a median of 10.6% (interquartile range 8.0-15.4%) per year, and all were implanted as destination therapy. Elderly and younger patients had similar durations of hospitalization in intensive care units and total lengths of hospital stays. Both age groups experienced similar rates of LVAD-related complications (i.e. stroke, bleeding, driveline infection and LVAD exchange), and the occurrence of LVAD complications did not impact survival in the elderly group compared with the younger group. Lastly, when compared with younger patients implanted as destination therapy, the elderly group also exhibited similar mid-term survival. This work strongly suggests that selected elderly adults can be scheduled for LVAD implantation.

Sections du résumé

BACKGROUND BACKGROUND
Left ventricular assist device (LVAD) implantation may be an attractive alternative therapeutic option for elderly patients with heart failure who are ineligible for heart transplantation.
AIM OBJECTIVE
We aimed to describe the characteristics and outcomes of elderly patients (i.e. aged≥70 years) receiving an LVAD.
METHODS METHODS
This observational study was conducted in 19 centres between 2006 and 2016. Patients were divided into two groups-younger (aged<70 years) and elderly (aged≥70 years), based on age at time of LVAD implantation.
RESULTS RESULTS
A total of 652 patients were included in the final analysis, and 74 patients (11.3%) were aged≥70 years at the time of LVAD implantation (maximal age 77.6 years). The proportion of elderly patients receiving an LVAD each year was constant, with a median of 10.6% (interquartile range 8.0-15.4%) per year, and all were implanted as destination therapy. Elderly and younger patients had similar durations of hospitalization in intensive care units and total lengths of hospital stays. Both age groups experienced similar rates of LVAD-related complications (i.e. stroke, bleeding, driveline infection and LVAD exchange), and the occurrence of LVAD complications did not impact survival in the elderly group compared with the younger group. Lastly, when compared with younger patients implanted as destination therapy, the elderly group also exhibited similar mid-term survival.
CONCLUSION CONCLUSIONS
This work strongly suggests that selected elderly adults can be scheduled for LVAD implantation.

Identifiants

pubmed: 32952086
pii: S1875-2136(20)30183-2
doi: 10.1016/j.acvd.2020.05.018
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

701-709

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Vincent Galand (V)

LTSI-UMR 1099, INSERM, Service de Cardiologie et Maladies Vasculaires, CHU de Rennes, Université de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France. Electronic address: vincent.galand35@gmail.com.

Erwan Flécher (E)

LTSI-UMR 1099, INSERM, Service de Cardiologie et Maladies Vasculaires, CHU de Rennes, Université de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France.

Céline Chabanne (C)

LTSI-UMR 1099, INSERM, Service de Cardiologie et Maladies Vasculaires, CHU de Rennes, Université de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France.

Bernard Lelong (B)

LTSI-UMR 1099, INSERM, Service de Cardiologie et Maladies Vasculaires, CHU de Rennes, Université de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France.

Céline Goéminne (C)

Cardiac Intensive Care Unit, Department of Cardiology, Department of Cardiac Surgery, Institut Coeur-Poumons, CHU de Lille, 59000 Lille, France.

André Vincentelli (A)

Cardiac Intensive Care Unit, Department of Cardiology, Department of Cardiac Surgery, Institut Coeur-Poumons, CHU de Lille, 59000 Lille, France.

Clément Delmas (C)

CHU de Toulouse, 31300 Toulouse, France.

Camille Dambrin (C)

CHU de Toulouse, 31300 Toulouse, France.

Karine Nubret (K)

LIRYC Institute, Hôpital Cardiologique du Haut-Lévêque, Université de Bordeaux, 33600 Pessac, France.

Mathieu Pernot (M)

LIRYC Institute, Hôpital Cardiologique du Haut-Lévêque, Université de Bordeaux, 33600 Pessac, France.

Michel Kindo (M)

Department of Cardiovascular Surgery, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Tam Hoang Minh (T)

Department of Cardiovascular Surgery, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Philippe Gaudard (P)

Department of Anaesthesiology, Critical Care Medicine and Cardiac Surgery, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Université de Montpellier, PhyMedExp, INSERM, CNRS, 34090 Montpellier, France.

Jean Marc Frapier (JM)

Department of Anaesthesiology, Critical Care Medicine and Cardiac Surgery, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Université de Montpellier, PhyMedExp, INSERM, CNRS, 34090 Montpellier, France.

Magali Michel (M)

Department of Cardiology and Heart Transplantation Unit, CHU de Nantes, 44093 Nantes, France.

Thomas Sénage (T)

Department of Cardiology and Heart Transplantation Unit, CHU de Nantes, 44093 Nantes, France.

Aude Boignard (A)

Department of Cardiology and Cardiovascular Surgery, Hôpital Albert Michallon, CHU de Grenoble, 38700 La Tronche, France.

Olivier Chavanon (O)

Department of Cardiology and Cardiovascular Surgery, Hôpital Albert Michallon, CHU de Grenoble, 38700 La Tronche, France.

Constance Verdonk (C)

Department of Cardiology and Cardiac Surgery, Hôpital Bichat, 75018 Paris, France.

Marylou Para (M)

Department of Cardiology and Cardiac Surgery, Hôpital Bichat, 75018 Paris, France.

Edeline Pelcé (E)

Department of Cardiac Surgery, Hôpital de la Timone, 13005 Marseille, France.

Vlad Gariboldi (V)

Department of Cardiac Surgery, Hôpital de la Timone, 13005 Marseille, France.

Matteo Pozzi (M)

Department of Cardiac Surgery, Hôpital Cardio-Vasculaire Louis Pradel, 69500 Bron, France.

Jean-François Obadia (JF)

Department of Cardiac Surgery, Hôpital Cardio-Vasculaire Louis Pradel, 69500 Bron, France.

Pierre Yves Litlzer (PY)

Department of Cardiology and Cardiovascular Surgery, Hôpital Charles Nicolle, 76000 Rouen, France.

Frédéric Anselme (F)

Department of Cardiology and Cardiovascular Surgery, Hôpital Charles Nicolle, 76000 Rouen, France.

Gerard Babatasi (G)

Department of Cardiology and Cardiac Surgery, Université de Caen and CHU de Caen, 14000 Caen, France.

Anne Flore Plane (AF)

Department of Cardiology and Cardiac Surgery, Université de Caen and CHU de Caen, 14000 Caen, France.

Fabien Garnier (F)

Department of Cardiology and Cardiac Surgery, CHU de Dijon, 21000 Dijon, France.

Marie Bielefeld (M)

Department of Cardiology and Cardiac Surgery, CHU de Dijon, 21000 Dijon, France.

David Hamon (D)

Department of Cardiology and Cardiac Surgery, Hôpital Henri Mondor, AP-HP, 94010 Créteil, France.

Costin Radu (C)

Department of Cardiology and Cardiac Surgery, Hôpital Henri Mondor, AP-HP, 94010 Créteil, France.

Thierry Bourguignon (T)

Department of Cardiology and Cardiac Surgery, CHRU de Tours, 37000 Tours, France.

Thibaud Genet (T)

Department of Cardiology and Cardiac Surgery, CHRU de Tours, 37000 Tours, France.

Romain Eschalier (R)

Cardiology Department, CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France.

Nicolas D'Ostrevy (N)

Cardiology Department, CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France.

Marie-Cécile Bories (MC)

Cardiology Department, Hôpital Européen Georges-Pompidou, AP-HP, 75015 Paris, France.

Eloi Marijon (E)

Cardiology Department, Hôpital Européen Georges-Pompidou, AP-HP, 75015 Paris, France.

Fabrice Vanhuyse (F)

Department of Cardiology and Cardiac Surgery, Hopital de Brabois, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France.

Hugues Blangy (H)

Department of Cardiology and Cardiac Surgery, Hopital de Brabois, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France.

Christophe Leclercq (C)

LTSI-UMR 1099, INSERM, Service de Cardiologie et Maladies Vasculaires, CHU de Rennes, Université de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France.

Raphaël P Martins (RP)

LTSI-UMR 1099, INSERM, Service de Cardiologie et Maladies Vasculaires, CHU de Rennes, Université de Rennes, 2, rue Henri-Le-Guilloux, 35000 Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH